LNAI Company Profile and Key Details

Lunai Bioworks Inc. generated EPS of -$7.55 over the past year. Five-year average earnings growth is -34.35%.

Short-term trend indicators are bullishly aligned (SMA20 -40.5%, SMA50 -51.94%, SMA200 -78.22%). The stock’s 14-day RSI is 30.14 (weak momentum), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.14% below its high and over 2.03% above its low. Average 10-day trading volume of 20.92 million shares is slightly above the 3-month average of 17.86 million, indicating heightened recent market interest.

Lunai Bioworks Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.61. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.15 and $5.50. With a market capitalization of about $5.78 million, Lunai Bioworks Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.49). Key stats such as the average daily volume over the past year has been around 22.07 million shares, trading with heavier-than-usual volume. Headquartered in Los Angeles, CA, Lunai Bioworks Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David H. Weinstein, the company employs approximately 29 people and listed since September 30, 2025. A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.

Lunai Bioworks Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.59 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.05, also above market averages.

Lunai Bioworks Inc. (NASDAQ:LNAI) shares are flat -1.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Lunai Bioworks Inc. trading at a premium to the broader market with a P/E of -0.06. Our AI forecast model points to short-term strength (1.66% over two weeks), a medium-term fall (-93.84% over three months), and a longer-term loss (-90.76% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lunai Bioworks Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.66%, with price expected at $0.33 by May 18, 2026, within a range of $0.24 to $0.43 3-Month Outlook: Projected fall of -93.84%, reaching $0.02 by July 31, 2026, with a range of $0.00 to $0.04. 1-Year Outlook: Projected loss of -90.76%, with price at $0.03 by May 04, 2027, within a range of $0.01 to $0.06.